

### ***Examiner's Amendment***

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mei Benni on 4/2/08.

1. In claim 11, lines 1-2, "a disease associated with inflammation" is replaced with "inflammation associated with a disease."

### ***Reasons for Allowance***

The following is an examiner's statement of reasons for allowance: the invention relates to a compounds of formula I and compositions thereof. The closest prior art of Tscherter et al., US 4,753,959, discloses similar compounds, but the compounds have  $\text{OHCH}_2$ - attached to pyran ring instead of  $\text{RSO}_2\text{CH}_2$ - in the instant compounds.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

### ***Telephone Inquiry***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taofiq A. Solola, PhD. JD., whose telephone number is (571) 272-0709.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on (571) 272-0867. The fax phone number for this Group is (571) 273-8300.

Art Unit: 1625

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

/Taofiq A. Solola/

Primary Examiner, 1625

April 3, 2008